|Have Questions?||Leave a Message or Start an on-line Chat|
CUSABIO meticulously generated the CLDN4 recombinant monoclonal antibody through a systematic approach. Initially, B cells were isolated from the spleen of an immunized animal, using the recombinant human CLDN4 protein as the immunogen during the immunization process. Following that, RNA was extracted from the B cells and reverse-transcribed into cDNA. By utilizing the cDNA as a template, the gene encoding the CLDN4 antibody was extended using a degenerate primer and inserted into a vector. The recombinant vector was then transfected into host cells, enabling the expression of the CLDN4 recombinant monoclonal antibodies. Subsequently, these antibodies were harvested from the cell culture supernatant and purified using affinity chromatography. ELISA was performed to confirm this antibody's reactivity with human CLDN4 protein, ensuring its specificity, reliability, and suitability for various applications.
There are currently no reviews for this product.